Cell replacement strategies aimed at reconstitution of the β-cell compartment in type 1 diabetes.
Emerging technologies in regenerative medicine have the potential to restore the β-cell compartment in diabetic patients, thereby overcoming the inadequacies of current treatment strategies and organ supply. Novel approaches include: 1) Encapsulation technology that protects islet transplants from host immune surveillance; 2) stem cell therapies and cellular reprogramming, which seek to regenerate the depleted β-cell compartment; and 3) whole-organ bioengineering, which capitalizes on the innate properties of the pancreas extracellular matrix to drive cellular repopulation. Collaborative efforts across these subfields of regenerative medicine seek to ultimately produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes.
Wake Forest School of Medicine, Winston-Salem, NC.
Giuseppe
G
Orlando
Pierre
P
Gianello
Marcus
M
Salvatori
Robert J
RJ
Stratta
Shay
S
Soker
Camillo
C
Ricordi
Juan
J
Domínguez-Bendala
D003922:Diabetes Mellitus, Type 1 / Q000473:pathology / Q000628:therapy*; D006801:Humans; D050417:Insulin-Secreting Cells / Q000473:pathology / Q000637:transplantation*; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D010179:Pancreas / Q000473:pathology / Q000502:physiology*; D012038:Regeneration; D033581:Stem Cell Transplantation / Q000379:methods*